DX-2930 (SHP643)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for DX-2930 (SHP643), covering 2020-05-11 to 2020-05-11. Get the full timeline:
Most recent: Clinical Trial Update: Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE [Phase 3]